VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+12.86%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$158M
AUM Growth
-$7.14M
(-4.3%)
Cap. Flow
-$21.5M
Cap. Flow
% of AUM
-13.64%
Top 10 Holdings %
Top 10 Hldgs %
5.64%
Holding
474
New
40
Increased
153
Reduced
231
Closed
49
Top Buys
| 1 |
Expedia Group
EXPE
|
$932K |
| 2 |
Prologis
PLD
|
$773K |
| 3 |
Gartner
IT
|
$769K |
| 4 |
Quanta Services
PWR
|
$762K |
| 5 |
Trane Technologies
TT
|
$759K |
Top Sells
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
$854K |
| 2 |
Arthur J. Gallagher & Co
AJG
|
$778K |
| 3 |
IDEX
IEX
|
$731K |
| 4 |
Tesla
TSLA
|
$719K |
| 5 |
VICI Properties
VICI
|
$715K |
Sector Composition
| 1 | Healthcare | 22.36% |
| 2 | Technology | 15.51% |
| 3 | Financials | 14.54% |
| 4 | Industrials | 9.65% |
| 5 | Energy | 8.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
351
Revolution Medicines
RVMD
$7.57B
| $102K | 0.06% |
3,540
-376
| -10% | -$10.8K |
|
|
CBAY
352
DELISTED
Cymabay Therapeutics
CBAY
| $101K | 0.06% |
4,278
-7,065
| -62% | -$167K |
|
353
Merus
MRUS
$5.1B
| $101K | 0.06% |
3,662
-69
| -2% | -$1.9K |
|
|
AGEN
354
Agenus
AGEN
$138M
| $101K | 0.06% |
6,081
+3,379
| +125% | +$56K |
|
355
Syndax Pharmaceuticals
SNDX
$1.47B
| $101K | 0.06% |
4,657
+125
| +3% | +$2.7K |
|
|
EXAI
356
DELISTED
Exscientia Plc American Depositary Shares
EXAI
| $101K | 0.06% |
15,692
+1,445
| +10% | +$9.26K |
|
357
Replimune Group
REPL
$494M
| $101K | 0.06% |
11,931
+7,715
| +183% | +$65K |
|
358
Arcus Biosciences
RCUS
$1.3B
| $100K | 0.06% |
5,251
+209
| +4% | +$3.99K |
|
359
Soleno Therapeutics
SLNO
$3.71B
| $100K | 0.06% |
+2,490
| New | +$100K |
|
360
Arcellx
ACLX
$4.03B
| $100K | 0.06% |
1,805
-800
| -31% | -$44.4K |
|
361
Pliant Therapeutics
PLRX
$114M
| $100K | 0.06% |
5,521
+1,455
| +36% | +$26.4K |
|
362
Immatics
IMTX
$761M
| $99.5K | 0.06% |
9,447
+1,184
| +14% | +$12.5K |
|
363
Arrowhead Research
ARWR
$4.02B
| $99.2K | 0.06% |
3,243
+444
| +16% | +$13.6K |
|
364
Ardelyx
ARDX
$1.57B
| $99K | 0.06% |
15,962
-8,633
| -35% | -$53.5K |
|
365
Krystal Biotech
KRYS
$4.35B
| $98.8K | 0.06% |
796
+30
| +4% | +$3.72K |
|
366
Precigen
PGEN
$1.3B
| $98.5K | 0.06% |
73,477
-6,277
| -8% | -$8.41K |
|
367
Rocket Pharmaceuticals
RCKT
$354M
| $98.1K | 0.06% |
3,274
-1,082
| -25% | -$32.4K |
|
|
AMAM
368
DELISTED
Ambrx Biopharma, Inc. Common Stock
AMAM
| $97.9K | 0.06% |
6,878
+85
| +1% | +$1.21K |
|
369
Iovance Biotherapeutics
IOVA
$901M
| $97.6K | 0.06% |
12,008
+603
| +5% | +$4.9K |
|
370
MoonLake Immunotherapeutics
MLTX
$3.77B
| $96.9K | 0.06% |
1,605
-2,082
| -56% | -$126K |
|
371
Akero Therapeutics
AKRO
$3.58B
| $96.9K | 0.06% |
4,148
+2,353
| +131% | +$54.9K |
|
372
Vera Therapeutics
VERA
$1.54B
| $96.7K | 0.06% |
+6,289
| New | +$96.7K |
|
373
Mineralys Therapeutics
MLYS
$2.7B
| $96.5K | 0.06% |
11,222
+5,017
| +81% | +$43.1K |
|
374
AbCellera Biologics
ABCL
$1.26B
| $96.5K | 0.06% |
16,894
+3,509
| +26% | +$20K |
|
375
IDEAYA Biosciences
IDYA
$2.38B
| $96.2K | 0.06% |
2,705
-1,272
| -32% | -$45.3K |
|